Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 106 participants.
Also called NCT01781390
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 106 participants
- Sponsor
- Mesoblast, Inc.
- Registry
-
NCT01781390 -
2010-020497-41
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT01781390. Randomized; quadruple masking; primary purpose treatment. Start 2013-03-11 (actual); primary completion 2021-04-06 (actual). Results posted on 2022-01-18.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction
- Acronym
- AMICI
- Condition
- Acute Myocardial Infarction
- Intervention (Other)
- Placebo
- Intervention (Biological)
- Mesenchymal Precursor Cells (MPC) 12.5 M
- Intervention (Biological)
- Mesenchymal Precursor Cells (MPC) 25 M
- Lead sponsor
- Mesoblast, Inc.
Record details
- Record id
cardio:ct-nct01781390- Content hash
4291d977b65406969a5501204e251775db800eff91858b53ef8a25e684c9eecb